141 related articles for article (PubMed ID: 36988284)
41. Pembrolizumab for the first-line treatment of non-small cell lung cancer.
Ninomiya K; Hotta K
Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786
[TBL] [Abstract][Full Text] [Related]
42. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.
Hori K; Nishio S; Ushijima K; Kasamatsu Y; Kondo E; Takehara K; Ito K
J Gynecol Oncol; 2021 Jul; 32(4):e64. PubMed ID: 34085798
[TBL] [Abstract][Full Text] [Related]
43. Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
Carey MS; Gawlik C; Fung-Kee-Fung M; Chambers A; Oliver T;
Gynecol Oncol; 2006 Apr; 101(1):158-67. PubMed ID: 16434086
[TBL] [Abstract][Full Text] [Related]
44. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
Geller MA; Ivy JJ; Ghebre R; Downs LS; Judson PL; Carson LF; Jonson AL; Dusenbery K; Vogel RI; Boente MP; Argenta PA
Gynecol Oncol; 2011 Apr; 121(1):112-7. PubMed ID: 21239048
[TBL] [Abstract][Full Text] [Related]
45. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
[TBL] [Abstract][Full Text] [Related]
46. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
47. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial).
Ito K; Tsubamoto H; Itani Y; Kuroboshi H; Fujita H; Nobunaga T; Coleman RL
Gynecol Oncol; 2011 Feb; 120(2):193-7. PubMed ID: 21075434
[TBL] [Abstract][Full Text] [Related]
48. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
49. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
50. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Fleming GF; Filiaci VL; Marzullo B; Zaino RJ; Davidson SA; Pearl M; Makker V; Burke JJ; Zweizig SL; Van Le L; Hanjani P; Downey G; Walker JL; Reyes HD; Leslie KK
Gynecol Oncol; 2014 Mar; 132(3):585-92. PubMed ID: 24456823
[TBL] [Abstract][Full Text] [Related]
51. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS; Filiaci VL; Mannel RS; Cohn DE; Matsumoto T; Tewari KS; DiSilvestro P; Pearl ML; Argenta PA; Powell MA; Zweizig SL; Warshal DP; Hanjani P; Carney ME; Huang H; Cella D; Zaino R; Fleming GF
J Clin Oncol; 2020 Nov; 38(33):3841-3850. PubMed ID: 33078978
[TBL] [Abstract][Full Text] [Related]
52. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
[TBL] [Abstract][Full Text] [Related]
54. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
55. Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer.
Kanno M; Yunokawa M; Nakabayashi M; Omi M; Ikki A; Mizusaki M; Nishimura M; Shimizu Y; Okamoto K; Tanaka Y; Fusegi A; Netsu S; Kurita T; Aoki Y; Tanigawa T; Matoda M; Okamoto S; Nomura H; Omatsu K; Sugiyama Y; Utsugi K; Takeshima N; Kanao H
Sci Rep; 2022 Jan; 12(1):166. PubMed ID: 34997003
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Post CCB; Westermann AM; Boere IA; Witteveen PO; Ottevanger PB; Sonke GS; Lalisang RI; Putter H; Meershoek-Klein Kranenbarg E; Braak JPBM; Creutzberg CL; Bosse T; Kroep JR
Gynecol Oncol; 2022 May; 165(2):223-229. PubMed ID: 35287967
[TBL] [Abstract][Full Text] [Related]
57. [Chemotherapy in metastatic or recurrent endometrial carcinoma].
Deppe G; Baumann P; Munkarah A
Zentralbl Gynakol; 2000; 122(7):355-60. PubMed ID: 10951705
[TBL] [Abstract][Full Text] [Related]
58. [Efficacy of cancer chemotherapy on patients with recurrent endometrial carcinoma].
Kakinoki S; Takizawa K
Nihon Rinsho; 2004 Oct; 62 Suppl 10():365-9. PubMed ID: 15535269
[No Abstract] [Full Text] [Related]
59. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
60. [Chemotherapy of endometrial cancer revisited].
Fehr MK; Wight E; Haller U
Gynakol Geburtshilfliche Rundsch; 1999; 39(3):110-20. PubMed ID: 10420053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
